betway必威登陆网址 (betway.com )学报››2022,Vol. 43››Issue (2): 120-124.DOI:10.3969/j.issn.2097-0005.2022.02.008

• 临床研究 •上一篇下一篇

生长抑素联合甲磺酸加贝酯治疗急性胰腺炎临床效果的Meta分析

吴瑞丽1(), 王振2(), 邓学杰2, 程征宇2, 周倩文3, 钟显飞2, 杨少奇4

  1. 1.betway必威登陆网址 附属消化病医院消化内科, 山东 济宁 272000
    2.乐山市人民医院消化内科, 四川 乐山 614000
    3.山东省戴庄医院, 山东 济宁 272051
    4.宁夏医科大学总医院消化内科, 宁夏 银川 750004
  • 收稿日期:2021-08-18出版日期:2022-02-25发布日期:2022-03-18
  • 通讯作者:王振
  • 作者简介:吴瑞丽,硕士,主治医师,主要从事胰腺炎方面的研究,E-mail:sdsxhbwrl@163.com
  • 基金资助:
    宁夏回族自治区重点研发计划(2018BEG020);宁夏高等学校一流学科建设项目(NXYLXK2017A05)

Meta-analysis of the clinical efficacy of somatostatin combined with gabexate mesylate in the treatment of acute pancreatitis

Ruili WU1(), Zhen WANG2(), Xuejie DENG2, Zhengyu CHENG2, Qianwen ZHOU3, Xianfei ZHONG2, Shaoqi YANG4

  1. 1.Digestive diseases hospital of Shandong First Medical University, Jining 272000, China
    2.Department of Gastroenterology, People's Hospital of Leshan, Leshan 614000, China
    3.Shandong Daizhuang Hospital, Jining 272051, China
    4.Department of Gastroenterology, General Hospital of Ningxia Medical University, Yinchuan 750004, China
  • Received:2021-08-18Online:2022-02-25Published:2022-03-18
  • Contact:Zhen WANG

摘要: 目的

探讨国内生长抑素联合甲磺酸加贝酯治疗急性胰腺炎(acute pancreatitis, AP)的临床效果。

方法

通过检索中国期刊全文数据库(CJFD)、大医医学、中国维普全文数据库、PubMed、EMbase等中英文数据库,收集国内应用生长抑素联合甲磺酸加贝酯治疗AP病例为研究对象,以单独应用生长抑素或甲磺酸加贝酯治疗AP的病例做对照的文献。筛选随机对照试验,结果用比值比(OR)及95%置信区间(95%CI)表示,评估指标为有效缓解率。按照设定的排除与纳入标准筛选文献、提取数据,并对纳入研究的方法学进行质量评估,采用RevMan 5.3软件进行Meta分析。

结果

纳入16项研究,共1 228例患者。其中9项研究生长抑素联合甲磺酸加贝酯组治疗AP缓解率与单用生长抑素组相比较,异质性检验χ2= 6.69,自由度(df) = 8,I2= 0%,P< 0.05,采用固定效应模型OR= 4.48,95%CI(2.84~7.08),提示联合用药优于单用生长抑素治疗;7项研究生长抑素联合甲磺酸加贝酯组治疗AP有效缓解率与单用甲磺酸加贝酯组的比较,异质性检验χ2= 1.81,df = 6,I2= 0%,P< 0.05,采用固定效应模型OR= 5.53,95%CI(3.15~9.70),提示联合用药优于单用甲磺酸加贝酯治疗。

结论

生长抑素联合甲磺酸加贝酯治疗AP能够有效提高治疗效果。

关键词:生长抑素,甲磺酸加贝酯,急性胰腺炎,Meta分析

Abstract: Objective

To evaluate the clinical efficacy of somatostatin combined with gabexate mesylate on the treatment of acute pancreatitis (AP).

Methods

CNKI Database, Wanfang Database, Dayi Medicine, PubMed,EMbase Database and other Chinese databases as well as English databases were searched by computer, and the cases of AP treated withsomatostatincombined with Gabexate mesylate in China were collected and screened for randomized controlled trials (RCT). The results were compared between the combined group and the control group using odds ratio (OR)and 95% Confidence Interval (CI) indexes. The evaluation indicator was the remission rate. According to the inclusion and exclusion criteria, the literature was selected, and data were extracted. Quality assessment of the included methodologies was performed, and then meta-analysis was performed by using RevMan 5.3 software.

Results

Sixteen studies including a total of 1 228 patients were adopted in the present study. Among them, 9 studies suggested that the remission rate of AP in somatostatin combined with Gabexate mesylate group was significantly improved compared with that in the somatostatin group alone (χ2= 6.69, df = 8,I2= 0%,P= 0.57, the effect modelOR= 4.48, 95%CIas (2.84~7.08), demonstrating that the combined treatment was superior to monotherapy in AP. Seven studies suggested that the remission rate of AP in somatostatin combined with Gabexate mesylate group was significantly improved compared with that in the gabexate mesylate group alone (χ2= 1.81, df =6,I2= 0%,P= 0.94, the effect modelOR= 5.53, 95%CIas (3.15~9.70), demonstrating that the combined treatment was superior in AP.

Conclusion

Somatostatin combined with gabexate mesylate can improve the effective response rate in the treatment of AP.

Key words:somatostatin,gabexate mesylate,acute pancreatitis,Meta-analysis